WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific ...

SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ... project completed in just 6 months. By leveraging single-use technology (SUT), the company scaled manufacturing from 4,000 to 16,000 ...

The entire clinical development process may last 6-11 years. WuXi’s phase 1 and phase ... can’t manufacture everything in-house. Biologics manufacturing requires quality certificates and ...

HONG KONG, March 25, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269), a leading global Contract Research, Development and Manufacturing ...

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ... project completed in just 6 months. By leveraging single-use technology (SUT), the company scaled manufacturing from 4,000 to 16,000 ...

Unveiled last year, the Singapore site will include manufacturing ... nearly 18.7 billion yuan ($2.6 billion). Taking COVID-related projects out of the mix, WuXi Biologics total 2024 revenue ...

Revenue: For the year ended December 31, 2024, the Group's revenue grew 9.6% YoY to RMB18,675. ... platforms that accelerate biologics development and manufacturing. Key platforms include WuXia ...

WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results on 18 March 2025.